Last reviewed · How we verify
olanzapine therapy
olanzapine therapy is a Atypical antipsychotic Small molecule drug developed by Eli Lilly and Company. It is currently FDA-approved for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Acute agitation associated with schizophrenia or bipolar disorder.
Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.
Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Acute agitation associated with schizophrenia or bipolar disorder.
At a glance
| Generic name | olanzapine therapy |
|---|---|
| Sponsor | Eli Lilly and Company |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor; Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Olanzapine antagonizes dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing positive symptoms of psychosis such as hallucinations and delusions. It also blocks serotonin 5-HT2A receptors, which contributes to its efficacy in treating negative symptoms and mood disturbances. The combined dopaminergic and serotonergic antagonism makes it effective across multiple psychiatric conditions.
Approved indications
- Schizophrenia
- Bipolar I disorder (acute mania and maintenance)
- Acute agitation associated with schizophrenia or bipolar disorder
- Treatment-resistant depression (in combination with fluoxetine)
Common side effects
- Weight gain
- Sedation/somnolence
- Dizziness
- Hyperglycemia/diabetes
- Hyperlipidemia
- Akathisia
- Orthostatic hypotension
Key clinical trials
- An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC (PHASE4)
- A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia (PHASE3)
- Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients (PHASE3)
- Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting (PHASE3)
- An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine (PHASE4)
- Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial (PHASE2)
- Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients (PHASE4)
- Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- olanzapine therapy CI brief — competitive landscape report
- olanzapine therapy updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI
Frequently asked questions about olanzapine therapy
What is olanzapine therapy?
How does olanzapine therapy work?
What is olanzapine therapy used for?
Who makes olanzapine therapy?
What drug class is olanzapine therapy in?
What development phase is olanzapine therapy in?
What are the side effects of olanzapine therapy?
What does olanzapine therapy target?
Related
- Drug class: All Atypical antipsychotic drugs
- Target: All drugs targeting Dopamine D2 receptor; Serotonin 5-HT2A receptor
- Manufacturer: Eli Lilly and Company — full pipeline
- Therapeutic area: All drugs in Psychiatry
- Indication: Drugs for Schizophrenia
- Indication: Drugs for Bipolar I disorder (acute mania and maintenance)
- Indication: Drugs for Acute agitation associated with schizophrenia or bipolar disorder
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing